Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G1IG
|
|||
| Former ID |
DIB002978
|
|||
| Drug Name |
F-16-131I
|
|||
| Synonyms |
Tenarad; Radiolabeled scFv antibody F-16 (solid tumor/hematological malignancy), Philogen
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1/2 | [1] | |
| Company |
Philogen SpA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tenascin (TNC) | Target Info | . | [2] |
| KEGG Pathway | PI3K-Akt signaling pathway | |||
| Focal adhesion | ||||
| ECM-receptor interaction | ||||
| MicroRNAs in cancer | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Beta3 integrin cell surface interactions | ||||
| Alpha9 beta1 integrin signaling events | ||||
| Syndecan-4-mediated signaling events | ||||
| Reactome | Integrin cell surface interactions | |||
| Syndecan interactions | ||||
| ECM proteoglycans | ||||
| WikiPathways | TGF beta Signaling Pathway | |||
| Focal Adhesion | ||||
| Syndecan interactions | ||||
| Extracellular matrix organization | ||||
| Integrin cell surface interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031840) | |||
| REF 2 | Tumor-Associated Fibroblasts and their Matrix. Springer. Margareta M. Mueller,Norbert E. Fusenig, 2011. Page(775). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.